International Journal of Clinical Research

Mycoplasma pneumoniae pneumonia refers primarily to inflammation of the lungs caused by Mycoplasma pneumoniae infection[1]. Epidemiology shows that the onset of the disease is low in age, mostly in children and young people, and often presents with dyspnea, cough, fatigue, decreased exercise tolerance, fever, and headache [2]. Most of the symptoms of Mycoplasma pneumoniae pneumonia are mild, but due to low immunity and narrowing of the respiratory lumen, pediatric patients are prone to a variety of complications such as atelectasis, myocardial damage, liver function damage, etc., which seriously affect the quality of life of children, and even endanger their life and health, which should arouse clinical attention [3]. At present, macrolides such as azithromycin are often used early in clinical practice to inhibit protein synthesis by obstructing the transpeptide process of Mycoplasma pneumoniae, thereby alleviating symptoms and shortening the course of disease in children with Mycoplasma pneumoniae pneumonia [4]. However, at present, most medical staff still have objections to the time of intravenous infusion of azithromycin in children with Mycoplasma pneumoniae pneumonia, in order to further study the effect and safety of different intravenous infusion times of azithromycin on the treatment effect and safety of children with Mycoplasma pneumoniae pneumonia, this study selected 180 cases of children with Mycoplasma pneumoniae treated in the pediatric department of this hospital as observation objects, the report is as follows.

Mycoplasma pneumoniae pneumonia; Azithromycin; Duration of symptom relief; Serological index CRP content; Incidence of adverse reactions